|17th February 2021||Peter A. Thompson||1,285,714||Open or private purchase||$3.50||$4,499,999.00|
|12th February 2021||Carl L Gordon||104,050||Grant/award etc.||$13.00||$1,352,650.00|
|12th February 2021||Advisors Llc Orbimed||104,050||Grant/award etc.||$13.00||$1,352,650.00|
|12th February 2021||Advisors Llc Orbimed||420,299||Grant/award etc.||$13.00||$5,463,887.00|
|12th February 2021||Carl L Gordon||420,299||Grant/award etc.||$13.00||$5,463,887.00|
|9th February 2021||Advisors Llc Orbimed||190,000||Open or private purchase||$17.00||$3,230,000.00|
|9th February 2021||Advisors Llc Orbimed||285,000||Open or private purchase||$17.00||$4,845,000.00|
|9th February 2021||Carl L Gordon||1,989,723||Conversion of derivative||$0.00|
|9th February 2021||Carl L Gordon||1,326,481||Conversion of derivative||$0.00|
|9th February 2021||Carl L Gordon||285,000||Open or private purchase||$17.00||$4,845,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.